A cluster randomized controlled trial for assessing POC-CCA test based praziquantel treatment for schistosomiasis control in pregnant women and their young children: study protocol of the freeBILy clinical trial in Madagascar
Daniela Fusco, Raphaël Rakotozandrindrainy, Rivo Andry Rakotoarivelo, Mala Rakoto‐Andrianarivelo, Njary Rakotozandrindrainy, Tahinamandranto Rasamoelina, Dewi Ismajani Puradiredja, Philipp Klein, Karl Stahlberg, Marie Dechenaud, Eva Lorenz, Anna Jaeger, Andrea Kreidenweiss, Pytsje T. Hoekstra, Ayôla Akim Adégnika, Elisa Sicuri, Paul L. A. M. Corstjens, Govert J. van Dam, Jürgen May, Norbert Georg Schwarz, Govert J. van Dam, Paul L. A. M. Corstjens, Claudia J. de Dood, Pytsje T. Hoekstra, Abena S. Amoah, M. I. Keshinro, Andrea Kreidenweiss, N. G. Schwarz, Daniela Fusco, Philipp Klein, Anna Jaeger, Eva Lorenz, Ayôla Akim Adégnika, Yabo Josiane Honkpéhèdji, Jean Claude Dejon‐Agobé, Romuald Beh, Mirabeau Mbong Ngwese, Moustapha Nzamba Maloum, A. Nguema Moure, Brice Meulah, Rivo Andry Rakotoarivelo, A. Ralaizandry, Mickael Radomanana, Raphaël Rakotozandrindrainy, Njary Rakotozandrindrainy, Marie Jeannine Solonirina, Mala Rakoto‐Andrianarivelo, T. Rasamoelina, Ravo Razafindrakoto, Elisa Sicuri, Céline Aerts
Abstract
BACKGROUND: Mass drug administration (MDA) of praziquantel is one of the main control measures against human schistosomiasis. Although there are claims for including pregnant women, infants and children under the age of 5 years in high-endemic regions in MDA campaigns, they are usually not treated without a diagnosis. Diagnostic tools identifying infections at the primary health care centre (PHCC) level could therefore help to integrate these vulnerable groups into control programmes. freeBILy (fast and reliable easy-to-use-diagnostics for eliminating bilharzia in young children and mothers) is an international consortium focused on implementing and evaluating new schistosomiasis diagnostic strategies. In Madagascar, the study aims to determine the effectiveness of a test-based schistosomiasis treatment (TBST) strategy for pregnant women and their infants and children up until the age of 2 years. METHODS: A two-armed, cluster-randomized, controlled phase III trial including 5200 women and their offspring assesses the impact of TBST on child growth and maternal haemoglobin in areas of medium to high endemicity of Schistosoma mansoni. The participants are being tested with the point of care-circulating cathodic antigen (POC-CCA) test, a commercially available urine-based non-invasive rapid diagnostic test for schistosomiasis. In the intervention arm, a POC-CCA-TBST strategy is offered to women during pregnancy and 9 months after delivery, for their infants at 9 months of age. In the control arm, study visit procedures are the same, but without the POC-CCA-TBST procedure. All participants are being offered the POC-CCA-TBST 24 months after delivery. This trial is being integrated into the routine maternal and child primary health care programmes at 40 different PHCC in Madagascar's highlands. The purpose of the trial is to assess the effectiveness of the POC-CCA-TBST for controlling schistosomiasis in young children and mothers. DISCUSSION: This trial assesses a strategy to integrate pregnant women and their children under the age of 2 years into schistosomiasis control programmes using rapid diagnostic tests. It includes local capacity building for clinical trials and large-scale intervention research. TRIAL REGISTRATION: Pan-African Clinical Trial Register PACTR201905784271304. Retrospectively registered on 15 May 2019.